238,204 Shares in Castle Biosciences, Inc. $CSTL Acquired by Advisors Capital Management LLCMarket Beat·2 days ago, 02:04 AMCSTL+3.86%
Castle Biosciences CEO Derek Maetzold sells USD 203,642 of common sharesPUBT·Aug 18 at 03:10 PMCSTL+3.86%
Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain TractionMarket Beat·Aug 13 at 12:01 AMCSTL+3.86%
Castle Biosciences CEO Derek Maetzold disposes of 45,016 common shares worth 1.4 millionPUBT·Aug 6 at 03:15 PMCSTL+3.86%
Castle Biosciences CEO Derek Maetzold reports disposal of common shares valued at $791,790.26PUBT·Aug 4 at 03:37 PMCSTL+3.86%
Castle Biosciences Reaffirmed at Buy as Strong Q2 and Raised 2026 Outlook Support 43% Upside to Unchanged $40 Price TargetTip Ranks·Aug 3 at 06:45 AMCSTL+3.86%
CSTL: Q2 2026 revenues up 20% YoY to $103.5M, driven by TissueCypher growth; net loss $2.1MQuartr·Jul 30 at 03:17 PMCSTL+3.86%
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga_article·Jul 30 at 04:05 PMNUWE+3.57%QURE-1.06%
Castle Biosciences shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY2026 sales guidance above estimates.benzinga_article·Jul 30 at 03:54 PMCSTL+3.86%
